UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Wainua slows disease progression for adults with hATTR-PN, per trial analysis

Source
Amyloidosis News Today

Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) — characterized by damage to the peripheral nerves found outside the brain and spinal cord — across a range of disease-causing mutations.

These findings, which researchers called “suggestive of consistent benefits,” come from an exploratory analysis of NEURO-TTRansform (NCT04136184), a now-completed large clinical trial that supported the approval of Wainua as the first treatment for hATTR-PN that can be self-administered by patients via an autoinjector.

The global Phase 3 trial, sponsored by Ionis Pharmaceuticals, had tested the effectiveness of the  injection therapy in people with hATTR-PN with a documented genetic mutation.